The estimated Net Worth of Capital, Llc Eco R1 is at least 148 百万$ dollars as of 14 August 2024. Capital R1 owns over 273,972 units of Akouos stock worth over 103,595,497$ and over the last 4 years Capital sold AKUS stock worth over 44,278,590$.
Sign up
Capital R1 AKUS stock SEC Form 4 insiders trading
Capital has made over 20 trades of the Akouos stock since 2020, according to the Form 4 filled with the SEC. Most recently Capital bought 273,972 units of AKUS stock worth 9,999,978$ on 14 August 2024.
The largest trade Capital's ever made was selling 5,887,610 units of Akouos stock on 1 December 2021 worth over 9,714,557$. On average, Capital trades about 1,192,170 units every 68 days since 2020. As of 14 August 2024 Capital still owns at least 7,794,996 units of Akouos stock.
You can see the complete history of Capital R1 stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Capital R1's mailing address?
Capital's mailing address filed with the SEC is 357 TEHAMA STREET #3, , SAN FRANCISCO, CA, 94103.
Insiders trading at Akouos
Over the last 4 years, insiders at Akouos have traded over 16,920,000$ worth of Akouos stock and bought 39,532,191 units worth 537,080,241$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Akouos executives and independent directors trade stock every 40 days with the average trade being worth of 24,448,882$. The most recent stock trade was executed by Acquisition Corp Eli Lilly ... on 30 November 2022, trading 29,992,668 units of AKUS stock currently worth 374,908,350$.
What does Akouos do?
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
What does Akouos's logo look like?
Complete history of Capital R1 stock trades at AnaptysBio Inc、Corvus Pharmaceuticals Inc、Prothena plc、Voyager Therapeutics Inc、Zymeworks BC Inc、Odonate Therapeutics Inc、Surface Oncology Inc、Akouos
Akouos executives and stock owners
Akouos executives and other stock owners filed with the SEC include:
-
Dr. Emmanuel Simons M.B.A., Ph.D.,
Co- Founder, Pres, CEO & Director -
Jennifer Anne Wellman M.S.,
Chief Operating Officer -
Jennifer Anne Wellman,
Chief Operating Officer -
Dr. Aaron Tward M.D., Ph.D.,
Chief Scientific Officer -
Stacy Price,
Chief Technical Officer -
Dr. Karoline K. Shair,
Sr. VP, Gen. Counsel, Chief Legal Officer & Corp. Sec. -
Dr. Alan K. Smith,
Chief Technology Officer -
Sachiyo Minegishi,
CFO, Treasurer, Assistant Sec. & Principal Accounting Officer -
Richard Smith M.D.,
Founder & Member of Scientific Advisory Board -
William F. Sewell Ph.D.,
Founder & Member of Scientific Advisory Board -
Dr. Luk H. Vandenberghe M.D., Ph.D.,
Founder & Member of Scientific Advisory Board -
Dr. Gregory Scott Robinson,
Chief Scientific Officer -
Dr. Michael John McKenna M.D.,
Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board -
Venture Partners X, L.P.Sof...,
-
Jennifer Anne Wellman,
CHIEF OPERATING OFFICER -
Asset Management, Lp Chen B...,
-
Edward T Mathers,
Director -
Kush Parmar,
Director -
Innovation Fund Ii, L.P. Pa...,
10% owner -
Bioventures Ltd Novartis Ag...,
-
Innovation Fund, Llc Partners,
10% owner -
Heather Preston,
Director -
Capital Management, L.P.Ra ...,
-
Capital, Llc Eco R1,
10% owner -
Saira Ramasastry,
Director -
Bio Venture Partners Fund I...,
-
Forest Baskett,
10% owner -
Carmen Chang,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Mohamad Makhzoumi,
10% owner -
Joshua Makower,
10% owner -
Scott D Sandell,
10% owner -
Paul Edward Walker,
10% owner -
Enterprise Associates 16, L...,
-
Ali Behbahani,
10% owner -
Peter W. Sonsini,
10% owner -
Advisers Llc Marshfield,
10% owner -
Michael John Mc Kenna,
Chief Medical Officer -
Sachiyo Minegishi,
Chief Financial Officer -
Gregory Scott Robinson,
Chief Scientific Officer -
Emmanuel Simons,
Chief Executive Officer -
Christopher M Smith,
Director -
Vicki L Sato,
Director -
Arthur Tzianabos,
Director -
Acquisition Corp Eli Lilly ...,